Cue Biopharma is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Our lead asset, CUE-221, is a novel anti-IgE antibody with a dual-mechanism of action, currently in Phase 2 development for allergic diseases. In addition, we developed the Immuno-STAT® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. CUE-401, our lead asset targeting autoimmune disease, is a bifunctional IL-2 and TGF-B program advancing towards Phase 1 and was designed to regulate inflammation and drive Treg-mediated tolerance.

Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.